News Releases

2019-09/02
United BioPharma successfully completes Taiwan FDA GMP inspection for its 2000L commercial scale manufacturing facility
1
2019-05/14
United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected Patients
2
2019-04/18
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption(N Engl J Med 2019; 380:1535-1545)
3
2019-04/18
United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of Medicine
4
2019-04/18
How an Experimental Injection Could Revolutionize HIV Treatment
5
2019-06/11
United BioPharma Receives US FDA Approval for UB-621 Phase 2 Trial in Recurrent Genital Herpes Patients
6
2019-05/21
United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infection
7
2019-04/18
Novel antibody may suppress HIV for up to four months
8
2019-04/17
Monoclonal antibody demonstrates ‘unprecedented’ virologic suppression in HIV study
9
2019-09/02
United BioPharma successfully completes Taiwan FDA GMP inspection for its 2000L commercial scale manufacturing facility
1
2019-05/14
United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected Patients
2
2019-04/18
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption(N Engl J Med 2019; 380:1535-1545)
3
2019-04/18
United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of Medicine
4
2019-04/18
How an Experimental Injection Could Revolutionize HIV Treatment
5
2019-06/11
United BioPharma Receives US FDA Approval for UB-621 Phase 2 Trial in Recurrent Genital Herpes Patients
6
2019-05/21
United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infection
7
2019-04/18
Novel antibody may suppress HIV for up to four months
8
2019-04/17
Monoclonal antibody demonstrates ‘unprecedented’ virologic suppression in HIV study
9